SPY751.17−0.79%QQQ676.07−1.76%BTC/USD68,894.53−3.47%DIA521.97−0.10%GLD356.12+0.35%TLT79.49−0.29%

Arcus Biosciences Inc

RCUSNYSE

Trade with Public

$17.35

-0.42-2.36%

Last update: Nov 13, 12:39 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Arcus Biosciences (RCUS) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Arcus Biosciences (RCUS) stock.

Analyst Consensus — 16 Analysts

13Buy

3Hold

# Analysts16

Latest Upgrades and Downgrades for Arcus Biosciences Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Leerink Partners	Daina Graybosch	PT Raise	Outperform	$46→$49
—	Truist Securities	Supawat Thongthip	PT Cut	Buy	$41→$40
—	Wedbush	Robert Driscoll	PT Cut	Outperform	$49→$45
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$45→$50
—	Truist Securities	Supawat Thongthip	PT Raise	Buy	$40→$41
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$43→$49
—	William Blair	Alethia Young	Initiate	Outperform	—
—	JP Morgan	Priyanka Grover	Initiate	Overweight	$41
—	Wedbush	Robert Driscoll	Maintained	Outperform	$43
—	TD Cowen	Tara Bancroft	Initiate	Buy	—
—	Truist Securities	Supawat Thongthip	PT Raise	Buy	$35→$40
—	Wells Fargo	Eva Fortea Verdejo	PT Raise	Equal-Weight	$23→$26
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$41→$43
—	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$32→$45
—	LifeSci Capital	Charles Zhu	Initiate	Outperform	$46
—	Truist Securities	Supawat Thongthip	Assumes	Buy	$30→$35
—	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$20→$22
—	Goldman Sachs	Richard Law	PT Raise	Buy	$30→$34
—	Wedbush	Robert Driscoll	PT Raise	Outperform	$37→$41
—	Citigroup	Yigal Nochomovitz	PT Raise	Buy	$44→$45

Arcus Biosciences Inc

Arcus Biosciences (RCUS) Stock Price Target 2026

Latest Upgrades and Downgrades for Arcus Biosciences Stock

Arcus Biosciences (RCUS) Stock Price Target 2026

Latest Upgrades and Downgrades for Arcus Biosciences Stock

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Arcus Biosciences Inc

Arcus Biosciences (RCUS) Stock Price Target 2026

Latest Upgrades and Downgrades for Arcus Biosciences Stock

Arcus Biosciences (RCUS) Stock Price Target 2026

Latest Upgrades and Downgrades for Arcus Biosciences Stock

Analyst Ratings News

PROLeerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PROTruist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

PROWedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

PROCitigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PROTruist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PROWedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

People Also Watch

People Also Watch

Analyst Ratings News

PROLeerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PROTruist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

PROWedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

PROCitigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PROTruist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PROWedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Lowers Price Target to $40

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Lowers Price Target to $45

PRO
Citigroup Maintains Buy on Arcus Biosciences, Raises Price Target to $50

PRO
Truist Securities Maintains Buy on Arcus Biosciences, Raises Price Target to $41

PRO
Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $49